Six Weeks After SAMHSA's Test Strip Ban, Here's What It Looks Like on the Ground

The SAMHSA guidance arrived on April 24, 2026. Seven pages, matter-of-fact tone, addressed to grantees. The substance: federal funds may no longer be used to purchase or distribute fentanyl test strips, clean syringes, sterile water for injection, or drug-use paraphernalia of any kind. The guidance framed the restriction as a clarification of existing policy under President Trump’s executive order directing SAMHSA grants to support only programs “incompatible with facilitating drug use.” The restriction updated July 2025 guidance that had already narrowed harm reduction funding and represented, as STAT News documented on April 27, “a clear shift from harm reduction.”

Six weeks have passed. Here is what six weeks looks like in practice.

Organizations that relied on SAMHSA Opioid Response Network funding to purchase fentanyl test strips are running down their inventories. The strips aren’t expensive in per-unit terms — roughly 50 cents each at scale — but organizations that were distributing thousands per week don’t have alternative budgets to absorb those costs. When the strips run out, they run out. The mobile units that brought test strips to people who couldn’t come to a fixed site are scaling back their routes. The National Association of Counties documented in May that county health departments operating under SAMHSA subgrants were seeking legal guidance about what the new restrictions actually prohibited, because the language was broad enough to create uncertainty about whether naloxone distribution programs would also be affected.

Naloxone — the overdose reversal medication — is not technically a harm reduction supply under the guidance’s language. But the guidance’s framing (“facilitating drug use”) is broad, and organizations are being cautious. When you’re operating on thin margins and a legal interpretation error could end your grant, you err conservative. That caution has real effects.

The SAMHSA restrictions came alongside the earlier cancellation of roughly $1.7 billion in block grant funding and $350 million in addiction and overdose prevention programs earlier in 2026. The April guidance wasn’t a standalone decision — it was the third or fourth in a series. The cumulative effect is a funding environment in which organizations that have spent five years building the relationships, routes, and trust needed to do effective harm reduction work are now making decisions about which services to cut.

The Drug Policy Alliance estimated in May that the combined federal funding cuts to overdose prevention programs could result in tens of thousands of fewer naloxone kits distributed annually and a significant contraction in the syringe service programs that are also HIV prevention infrastructure. The math on what that means for overdose deaths isn’t linear — the relationship between test strip availability and overdose mortality depends on dosing patterns, drug supply variability, and whether people actually change behavior based on results — but the direction is not ambiguous.

The Lancet analysis published last year found that the recent overdose death decline is primarily driven by market dynamics, not treatment or harm reduction expansion. That finding is often cited by the administration as evidence that harm reduction cuts won’t reverse progress. The counterargument, made by every public health researcher who has read the study, is the obvious one: supply-driven improvements are not stable, and the harm reduction infrastructure is specifically what you need intact when they’re not.

The organizations losing test strips today are the same ones that will be asked to respond when conditions change. Building that infrastructure takes years. Losing it takes six weeks.